1237737-89-1

Basic information

• Product Name: 4-(6-ethylbenzothiazol-2-yl)-2-methylphenylamine
• Synonyms: 4-(6-ethylbenzothiazol-2-yl)-2-methylphenylamine
• CAS NO: 1237737-89-1
• Molecular Weight: 268.382
• Mol File: 1237737-89-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(6-ethylbenzothiazol-2-yl)-2-methylphenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6-ethylbenzothiazol-2-yl)-2-methylphenylamine(1237737-89-1)
• EPA Substance Registry System: 4-(6-ethylbenzothiazol-2-yl)-2-methylphenylamine(1237737-89-1)

Safety Data

• Hazardous Substances Data: 1237737-89-1(Hazardous Substances Data)

Upstream product

• 1237737-86-8 6-ethyl-2-(3-methyl-4-nitrophenyl)benzothiazole 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 35675-46-8 3-methyl-4-nitro-benzoyl chloride 
• 1257874-91-1 N-(4-ethylphenyl)-3-methyl-4-nitrothiobenzamide 
• 349406-92-4 N-(4-ethylphenyl)-3-methyl-4-nitrobenzamide 
• 589-16-2 4-aminoethylbenzene 
• 2486-70-6 4-amino 3-methylbenzoic acid 
• 90382-10-8 2-amino-5-ethylbenzothiazole 

Relevant articles and documents

Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells

We have designed and synthesized a new series of 1-benzothiazolylphenylbenzotriazoles 9a-p and studied their antimetastatic mechanism involved in photosensitive effects induced by UVA in oral cancer cell Ca9-22. Our results revealed that the compounds plus UVA significantly suppressed migration and invasion, as detected by wound healing assay and Boyden chamber assay. Quantitative RT-PCR assay indicated that compound 9i plus UVA induced an antimetastatic effect through up-regulation of syndecan-1 and TIMP-3 and down-regulation of heparanase, MMP-2 and MMP-9 mRNA expressions. Western blot analysis showed that Ca9-22 treated with 9i plus UVA resulted in decreased levels of p-EGFR and p-ERK, MMP-2 and MMP-9, and an increased level of TIMP-3. These results are the first to report the function of UVA-activated 1-benzothiazolylphenylbenzotriazoles in tumor metastasis and their underlying molecular mechanism, and thus suggest that compound 9i plus PDT may serve as a potential ancillary modality for the treatment of oral cancer.

Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents

Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315-400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects induced by UVA-activated 6 in BCC cells are carried out in the present article. 6-UVA-treated cells displayed several features of apoptosis, including an increase in the sub-G1 population, a significantly increased annexin V binding, and activation of caspase-3. 6-UVA induced a decrease in mitochondrial membrane potential (Δψ mt) and ATP via enhanced ROS generation and promoted phosphorylation of extracellular signal-regulated kinase (ERK) and p38 MAPK expression. These results suggest that 6-UVA elicits photosensitive effects in mitochondria processes which involve ERK and p38 activation, and ultimately lead to BCC cell apoptosis.